{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:16:50Z","timestamp":1790691410565,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T00:00:00Z","timestamp":1596844800000},"content-version":"vor","delay-in-days":373,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ymthe.2019.05.018","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T22:33:18Z","timestamp":1559601198000},"page":"1495-1506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity"],"prefix":"10.1016","volume":"27","author":[{"given":"John","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Nietupski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyejung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh S.","family":"Bangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Silvescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Wilper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Tietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyou","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng H.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.05.018_bib1","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"The GM2 Gangliosidoses","author":"Gravel","year":"2014"},{"key":"10.1016\/j.ymthe.2019.05.018_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ymgme.2017.12.432","article-title":"Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study","volume":"123","author":"Nestrasil","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.05.018_bib3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","article-title":"Infantile gangliosidoses: Mapping a timeline of clinical changes","volume":"121","author":"Jarnes Utz","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.05.018_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.neuroscience.2016.10.047","article-title":"AAV-mediated gene delivery attenuates neuroinflammation in feline Sandhoff disease","volume":"340","author":"Bradbury","year":"2017","journal-title":"Neuroscience"},{"key":"10.1016\/j.ymthe.2019.05.018_bib5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/hmg\/ddy012","article-title":"Intravenous administration of scAAV9-Hexb normalizes lifespan and prevents pathology in Sandhoff disease mice","volume":"27","author":"Niemir","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymthe.2019.05.018_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12035-013-8605-5","article-title":"Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on \u03b2-hexosaminidase activity in Sandhoff fibroblasts","volume":"50","author":"Chiricozzi","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymthe.2019.05.018_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s11064-012-0718-0","article-title":"Therapeutic effects of stem cells and substrate reduction in juvenile Sandhoff mice","volume":"37","author":"Arthur","year":"2012","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ymthe.2019.05.018_bib8","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1172\/JCI2127","article-title":"Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice","volume":"101","author":"Norflus","year":"1998","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2019.05.018_bib9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1182\/blood.V97.1.327","article-title":"Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation","volume":"97","author":"Jeyakumar","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.05.018_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ana.22262","article-title":"Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis","volume":"69","author":"Tsuji","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymthe.2019.05.018_bib11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1172\/JCI85300","article-title":"Protease-resistant modified human \u03b2-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model","volume":"126","author":"Kitakaze","year":"2016","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2019.05.018_bib12","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.nbd.2004.04.012","article-title":"Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease","volume":"16","author":"Andersson","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2019.05.018_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.neuint.2007.12.001","article-title":"N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice","volume":"52","author":"Baek","year":"2008","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ymthe.2019.05.018_bib14","doi-asserted-by":"crossref","first-page":"e21758","DOI":"10.1371\/journal.pone.0021758","article-title":"Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease","volume":"6","author":"Ashe","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2019.05.018_bib15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-Associated Virus-Based Gene Therapy for CNS Diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2019.05.018_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","article-title":"Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9","volume":"241","author":"Saraiva","year":"2016","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.ymthe.2019.05.018_bib17","doi-asserted-by":"crossref","first-page":"e0028","DOI":"10.5041\/RMMJ.10162","article-title":"Hematopoietic stem cell transplantation-50 years of evolution and future perspectives","volume":"5","author":"Henig","year":"2014","journal-title":"Rambam Maimonides Med. J."},{"key":"10.1016\/j.ymthe.2019.05.018_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/mt.2014.12","article-title":"A Hitchhiker\u2019s guide to the blood-brain barrier: in trans delivery of a therapeutic enzyme","volume":"22","author":"Sands","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.05.018_bib19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1023\/A:1025902113005","article-title":"The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement","volume":"26","author":"Cox","year":"2003","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2019.05.018_bib20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/21678707.2014.899148","article-title":"A systematic review on effectiveness and safety of eliglustat for type 1 Gaucher disease","volume":"2","author":"Smid","year":"2014","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymthe.2019.05.018_bib21","doi-asserted-by":"crossref","first-page":"6388","DOI":"10.1073\/pnas.96.11.6388","article-title":"Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin","volume":"96","author":"Jeyakumar","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.05.018_bib22","doi-asserted-by":"crossref","first-page":"e43310","DOI":"10.1371\/journal.pone.0043310","article-title":"Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease","volume":"7","author":"Cabrera-Salazar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.05.018_bib23","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.05.018_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymthe.2019.05.018_bib25","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2019.05.018_bib26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11307-017-1099-1","article-title":"Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration","volume":"20","author":"Beckers","year":"2018","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.ymthe.2019.05.018_bib27","doi-asserted-by":"crossref","first-page":"E1065","DOI":"10.3390\/ijms17071065","article-title":"Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2019.05.018_bib28","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-12-758409","article-title":"Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy","volume":"129","author":"Cox","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.05.018_bib29","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/ajh.24877","article-title":"Outcomes after 18\u00a0months of eliglustat therapy in treatment-na\u00efve adults with Gaucher disease type 1: The phase 3 ENGAGE trial","volume":"92","author":"Mistry","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymthe.2019.05.018_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1172\/JCI5542","article-title":"A genetic model of substrate deprivation therapy for a glycosphingolipid storage disorder","volume":"103","author":"Liu","year":"1999","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2019.05.018_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.expneurol.2017.09.012","article-title":"Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease","volume":"299","author":"Seyrantepe","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymthe.2019.05.018_bib32","doi-asserted-by":"crossref","first-page":"e1001118","DOI":"10.1371\/journal.pgen.1001118","article-title":"Mice doubly-deficient in lysosomal hexosaminidase A and neuraminidase 4 show epileptic crises and rapid neuronal loss","volume":"6","author":"Seyrantepe","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymthe.2019.05.018_bib33","doi-asserted-by":"crossref","first-page":"9975","DOI":"10.1073\/pnas.91.21.9975","article-title":"Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease","volume":"91","author":"Yamanaka","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.05.018_bib34","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.05.018_bib35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ymgme.2017.05.015","article-title":"Psychosine, a marker of Krabbe phenotype and treatment effect","volume":"121","author":"Escolar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.05.018_bib36","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"23","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.05.018_bib37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.05.018_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/bj20030613","article-title":"Lyso-glycosphingolipids mobilize calcium from brain microsomes via multiple mechanisms","volume":"375","author":"Lloyd-Evans","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymthe.2019.05.018_bib39","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/oxfordjournals.jbchem.a124584","article-title":"The synthetic pathway for glucosylsphingosine in cultured fibroblasts","volume":"116","author":"Yamaguchi","year":"1994","journal-title":"J.\u00a0Biochem."},{"key":"10.1016\/j.ymthe.2019.05.018_bib40","doi-asserted-by":"crossref","first-page":"e29074","DOI":"10.1371\/journal.pone.0029074","article-title":"Lyso-GM2 Ganglioside: A Possible Biomarker of Tay-Sachs Disease and Sandhoff Disease","volume":"6","author":"Kodama","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2019.05.018_bib41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1515\/bchm3.1986.367.1.241","article-title":"Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain","volume":"367","author":"Neuenhofer","year":"1986","journal-title":"Biol. Chem. Hoppe Seyler"},{"key":"10.1016\/j.ymthe.2019.05.018_bib42","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","article-title":"Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation","volume":"97","author":"Wada","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.05.018_bib43","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/brain\/awg089","article-title":"Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis","volume":"126","author":"Jeyakumar","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.ymthe.2019.05.018_bib44","doi-asserted-by":"crossref","first-page":"8425","DOI":"10.1073\/pnas.0400625101","article-title":"Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.05.018_bib45","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1471-4159.2005.02986.x","article-title":"Specific induction of macrophage inflammatory protein 1-alpha in glial cells of Sandhoff disease model mice associated with accumulation of N-acetylhexosaminyl glycoconjugates","volume":"92","author":"Tsuji","year":"2005","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2019.05.018_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/srep00573","article-title":"The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis","volume":"2","author":"Tanaka","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2019.05.018_bib47","doi-asserted-by":"crossref","first-page":"e0120194","DOI":"10.1371\/journal.pone.0120194","article-title":"Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease","volume":"10","author":"Zigdon","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.05.018_bib48","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12974-016-0570-2","article-title":"Induction of the type I interferon response in neurological forms of Gaucher disease","volume":"13","author":"Vitner","year":"2016","journal-title":"J.\u00a0Neuroinflammation"},{"key":"10.1016\/j.ymthe.2019.05.018_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13550-017-0305-0","article-title":"Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates","volume":"7","author":"Hillmer","year":"2017","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ymthe.2019.05.018_bib50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.nicl.2015.01.009","article-title":"Increased in\u00a0vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28","volume":"7","author":"Z\u00fcrcher","year":"2015","journal-title":"Neuroimage Clin."},{"key":"10.1016\/j.ymthe.2019.05.018_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s13139-017-0475-8","article-title":"Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases","volume":"51","author":"Alam","year":"2017","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ymthe.2019.05.018_bib52","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbd.2015.11.001","article-title":"TSPO in a murine model of Sandhoff disease: presymptomatic marker of neurodegeneration and disease pathophysiology","volume":"85","author":"Loth","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2019.05.018_bib53","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsbmb.2015.07.007","article-title":"Therapeutic actions of translocator protein (18\u00a0kDa) ligands in experimental models of psychiatric disorders and neurodegenerative diseases","volume":"154","author":"Arbo","year":"2015","journal-title":"J.\u00a0Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.ymthe.2019.05.018_bib54","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/01.wnl.0000194225.78917.de","article-title":"Substrate reduction therapy in the infantile form of Tay-Sachs disease","volume":"66","author":"Bembi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ymthe.2019.05.018_bib55","first-page":"425","article-title":"Cerebrospinal fluid infusion of alglucerase in the treatment of acute neuronopathic Gaucher\u2019s disease","volume":"38","author":"Bembi","year":"2005","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymthe.2019.05.018_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1015137917508","article-title":"Glycolipid analysis of different tissues and cerebrospinal fluid in type II Gaucher disease","volume":"25","author":"Gornati","year":"2002","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2019.05.018_bib57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11307-014-0743-2","article-title":"Preclinical imaging evaluation of novel TSPO-PET ligand 2-(5,7-Diethyl-2-(4-(2-[(18)F]fluoroethoxy)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)-N,N-diethylacetamide ([ (18)F]VUIIS1008) in glioma","volume":"16","author":"Tang","year":"2014","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.ymthe.2019.05.018_bib58","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13550-017-0343-7","article-title":"Evaluation of the novel TSPO radiotracer [18F] VUIIS1008 in a preclinical model of cerebral ischemia in rats","volume":"7","author":"Pulagam","year":"2017","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ymthe.2019.05.018_bib59","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1074\/mcp.M112.017707","article-title":"Platform-independent\u00a0and label-free quantitation of proteomic data using MS1 extracted ion chromatograms in skyline: application to protein acetylation and phosphorylation","volume":"11","author":"Schilling","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ymthe.2019.05.018_bib60","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1021\/ac303554e","article-title":"Matrix precoated targets for direct lipid analysis and imaging of tissue","volume":"85","author":"Yang","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ymthe.2019.05.018_bib61","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1021\/ac202383m","article-title":"Enhanced sensitivity for high spatial resolution lipid analysis by negative ion mode matrix assisted laser desorption ionization imaging mass spectrometry","volume":"84","author":"Angel","year":"2012","journal-title":"Anal. Chem."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619302655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619302655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:54:10Z","timestamp":1761501250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619302655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1525001619302655"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.018","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736011845.793563299","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}